| Literature DB >> 16434199 |
Wenxin Gu1, Inna Nusinzon, Ronald D Smith, Curt M Horvath, Richard B Silverman.
Abstract
Suberoylanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylase, is used in clinical trials for a variety of advanced cancers. Twelve new analogs of SAHA were synthesized and tested as in vitro inhibitors of isolated histone deacetylases (HDACS) and in vivo inhibitors of interferon regulated transcriptional responses (a marker for HDAC activity). The analogs containing an alpha-mercaptoketone or an alpha-thioacetoxyketone were more potent than SAHA in both assays.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16434199 DOI： 10.1016/j.bmc.2005.12.047
Source DB: PubMed Journal: Bioorg Med Chem ISSN： 0968-0896 Impact factor: 3.641